Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Uniquity Bio Appoints Will Kane President and CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Uniquity Bio Appoints Will Kane President and CEO

Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

By: Rachel Klemovitch

Assistant Editor

Uniquity Bio, a clinical-stage drug development company backed by Blackstone Life Sciences, appointed Will Kane as President and CEO. Kane will support strategy and growth as Uniquity advances Solrikitug, its lead asset, in the completion of three Phase II trials and prepares for Phase III.

Kane succeeds Brian Lortie, co-founder and former CEO, who stepped down from the company in June 2025. 

Kane joins with more than three decades of biopharmaceutical leadership experience and a track record of building high-performing teams, leading transformational change, and delivering business results across a range of therapeutic areas. 

Before joining Uniquity Bio, Kane served as president and chief commercial officer at Anthos Therapeutics, which was recently acquired by Novartis. He has also held senior leadership roles at Karuna Therapeutics, BioXcel Therapeutics, Allergan, and Pfizer.

Solrikitug is a highly potent monoclonal antibody targeting Thymic Stromal Lymphopoietin (TSLP), a clinically validated driver of inflammatory response. It is currently advancing through separate Phase II trials in asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE). 

Uniquity is pursuing potential best-in-class efficacy and convenient dose optimization across these conditions. By preventing the binding of TSLP to its receptors, solrikitug has potential utility in a wide array of immunology and inflammation diseases. 

Uniquity is also in the process of identifying bispecific candidates for clinical testing, combining solrikitug with other key inflammatory targets to enhance efficacy and/or broaden the applicable patient population in specific indications.

“Will’s leadership, combined with his operational and commercial experience, are the right fit for Uniquity at this stage of the organization’s evolution and development,” said Bill Meury, chairman of the Uniquity Bio board of directors. “The company has tremendous potential, with a seasoned leadership team, an exciting asset in development and a real need for solrikitug in several different indications. As I look ahead to the next phase of Uniquity, I am eager to see how this important work makes a difference for people around the world.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters